Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MERRELL DOW's SELDANE JUNE SALES TO RETAILERS TOP $2 MIL

Executive Summary

MERRELL DOW's SELDANE JUNE SALES TO RETAILERS TOP $2 MIL on the basis of 161,000 total Rxs written during the month for the nonsedative antihistamine, Pharmaceutical Data Services (PDS) reported in its just-released July Alpha Gram. After generating 16,000 new prescriptions during the last few days of May following FDA approval on May 8, Seldane's June new prescriptions totalled 146,000, according to PDS figures. PDS showed Seldane (terfenadine) sales at $217,000 (at retail acquisition cost) in May and at $2.1 mil. in June. "Seldane, already the number one single entity allergy product in Europe, appears to be headed in the same direction in the U.S.," PDS commented. "In June, Seldane catapulted to the number two position in terms of total U.S. retail prescriptions dispensed and sales dollars in the single entity prescription antihistamine U.S. retail market." The preliminary figures indicate that Merrell Dow may now have its second successful market launch in two years. According to PDS data for 1984, the firm's Rx chewing gum Nicorette was the most successful product launch of last year with $34.4 mil. in sales (at retail acquisition cost) in just ten months. Seldane, indicated for the symptomatic relief of seasonal allergic rhinitis, is the first non-sedating antihistamine to reach the market in the U.S. Several other firms have nonsedative antihistamine agents reach the market in the U.S. Several other firms have nonsedative antihistamine agents under development, including J&J (Hismanal) and Robins (mequitazine).

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

PS008743

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel